SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-004272
Filing Date
2020-01-09
Accepted
2020-01-09 08:05:39
Documents
14
Period of Report
2020-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d861163d8k.htm   iXBRL 8-K 31338
2 EX-99.1 d861163dex991.htm EX-99.1 22442
6 GRAPHIC g861163g0109072457614.jpg GRAPHIC 3544
  Complete submission text file 0001193125-20-004272.txt   185776

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20200108.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20200108_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20200108_pre.xml EX-101.PRE 10950
9 EXTRACTED XBRL INSTANCE DOCUMENT d861163d8k_htm.xml XML 3238
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20517056
SIC: 2834 Pharmaceutical Preparations